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This article analyzes the emerging ethical and legal requirements for informed consent in 
pharmacogenomic research. It reviews how policies at the international, regional and 
national levels have responded to the ethical challenges raised by this new research area. 
It concludes that the pharmacogenomic policy framework is still in its infancy and needs 
to be further developed to answer the challenges raised by this important discipline.  
 
 
Central tenets of the informed consent 
process have for a long time been the 
ethical and legal principles of autonomy and 
integrity. These principles explain the 
importance of obtaining voluntary, informed 
consent in medical research. However, the 
emergence of the genetic and genomic era 
has led a growing number of authors to note 
that the informed consent process is in need 
of updating and restructuring to effectively 
address new realities faced by genetic 
researchers and research participants.1 This 
is because many research studies that have 
been made possible since the sequencing of 
the human genome are thought to have 
significance for the family unit, the 
community, and even society as a whole, as 
well as for individual research participants. 
 
Ethicists have argued that an approach to 
consent that is concerned with both the 
societal and individual implications of 
participation in research2 would facilitate the 
use of biological samples and would thus 
result in superior and more rapid 
advancements for the treatment of disease. 
 
Pharmacogenomics, the study of the 
relationship between genetics and drug 
response, is one example of research that 
holds the potential for great societal benefit 
and may thus require an approach to 
consent that is based on communal values. 
This issue of GenEdit has sought--through 
comparative analysis of national, regional 
and international guiding documents--to 
discover whether ethicists and policy makers 
are emphasizing communal values, such as 
reciprocity, solidarity, universality and 
citizenship in their guidance of 
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pharmacogenomic research.  The purpose 
of this study is not to develop a specific 
model of consent, but rather to provide an 
overview of emerging issues with regard to 
informed consent in this novel research 
area.  In particular, it questions whether 
informed consent standards are being 
relaxed to encourage advances in 
pharmacogenomics; or whether they are 
being strengthened on account of the 
perception of new risks. It further questions 
whether there is sufficient guidance to direct 
pharmacogenomic researchers on how to 
fulfill their informed-consent related 
obligations.  
 
Pharmacogenomics and consent:  
A comparative study 
Pharmacogenomics has the potential to 
dramatically improve that way that drugs are 
both developed and prescribed. However, 
pharmacogenomics, like most new areas of 
medical research, also raises a number of 
ethical issues. Does this mean that 
pharmacogenomics should have its own 
ethical framework? Proponents of this 
research believe that it should. They argue 
that since pharmacogenomics is limited to 
studying drug-response, it does not entail 
the risk of generating potentially stigmatizing 
information about disease susceptibility, and 
should thus be subjected to less 
constraining rules as compared to genetic 
susceptibility research.3 The validity of this 
argument remains subject of debate and to 
date, little consensus has emerged between 
the various stakeholders involved in 
pharmacogenomic research.4
 
Nonetheless, recognition of the increasing 
relevancy of pharmacogenomics in relation 
to drug discovery, clinical studies, and 
perhaps eventually the drug approval 
process, has resulted in much discussion on 
how to best deal with the issue of consent in 
pharmacogenomic research.  In this study, 
we seek to uncover emerging trends on this 
issue from the guiding documents published 
at the national, regional and international 
levels.  Part (A) will explain the methodology 
of the study. Part (B) will explain the results 
in relation to each contentious issue outlined 
in the methodology.  Finally, in the 
conclusion, we will identify any noticeable 
trends that emerge in the existing guidelines 
and explain where more direction may be 
necessary to ensure that this research 
advances in an ethically sound and efficient 
manner.   
 
(A) Methodology 
Using the HumGen International Database 
of Laws and Policies,5Medline, PubMed, 
Google, Google Scholar, Lexis Nexis  and 
the WHO International Digest of Health 
Legislation, policy documents and 
recommendations from five international 
organizations and coalitions,6 three 
European regional organizations and 16  
countries were identified.7 Of these, 
surprisingly few documents, only 4 
international,8 2 European,9 and 7 
national,10 focused explicitly or implicitly on 
pharmacogenomics. Using these 
documents, we analyzed the emerging 
ethical trends around five key issues in the 
pharmacogenomics consent process, 
including: (i) scope of consent, (ii) duration 
of consent, (iii) confidentiality and coding of 
research samples, (iv) return of research 
results, and (v) consent to ‘add-on’ studies 
in the context of clinical trials.  
 
(B) Results 
(i) Scope of consent 
The scope of consent refers to the breadth 
of research permissible in a given 
pharmacogenomic study. While some 
policies permit broad consent for unspecified 
purposes,11 others take a much more 
restrictive approach, requiring clear and 
specific explanations of potential future 
research.12 The majority of texts advocate 
compromise solutions so that the rights of 
research participants are respected but at 
the same time freedom of research is not 
curtailed by overly specific consent 
clauses.13 For example, according to the 
European Pharmaceutical Industry 
Association, the scope of consent should 
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strike “a reasonable balance between 
describing the research…and not curtailing 
flexibility for future use.”14 The US 
Consortium on Pharmacogenetics 
advocates that a “reasonable policy is to 
obtain consent to a range of related studies 
over time.”15 Another proposed solution is to 
permit unrestricted use of donor samples 
only after the samples have been 
anonymized and are no longer traceable 
back to an individual.  UK’s Nuffield Council 
on Bioethics favours this approach, 
explaining that “it is permissible to request 
broad consent to the use of samples which 
are anonymous or anonymised.”16  Another 
approach mentioned in the Nuffield Council 
report is to permit the consent to future use 
only when it is contained in a separate 
consent form. Thus, we find that although 
there is to date no general consensus on 
any one specific approach to consent scope, 
intermediate solutions are favoured by the 
majority of existing guidelines discussing 
this issue.  
 
TABLE 1:  
Document Recommendation on the scope of consent  
International: Pharmacogenetics Working Group 
(2002): Elements of Informed Consent for 
Pharmacogenetic Research 
“The specific purpose of the study should be clearly described 
including both short-term objectives and potential long-term 
applications” 
International: Council for International Organizations of 
Medical Sciences (2005) Pharmacogenomics: 
Towards improving treatment with medicines 
“For informed consent documents, it is recommended that “field 
of use” needs to be well described but that appropriate broad use 
may also be permitted” 
Europe: European Federation of Pharmaceutical  
Industries and Associations (2006): Key Messages 
Surrounding Pharmacogenetics 
 
“The consent process must strike a reasonable balance between 
describing procedures and purposes of the research in sufficient 
detail while not being overly restrictive and curtailing flexibility for 
future use of data samples based on evolving scientific 
knowledge and technology” 
Belgium: Consultative Committee on Belgian Bioethics 
(2003) Opinion (No 26) December 15, 2003 
concerning the introduction of pharmacogenetics in 
experimental protocols 
Sample donors can consent to future, unspecified use of their 
biological samples  
Italy: A collaboration of research groups (2002): Italian 
Proposed Guidelines for the Evaluation of 
Pharmacogenetic Research 
“The collection of biological samples without a clear aim, or only 
for unidentified future use should be prohibited.”  However, the 
patient can authorize use for a study in the same research area if 
it is anonymized. If the sample is identifiable, new consent is 
required   
United Kingdom: Nuffield Council on Bioethics (2003): 
Pharmacogenetics: Ethical Issues 
“It is permissible to request broad consent to the use of samples 
which are anonymous or anonymized.  Where samples… are 
coded or identified, broad consent… may be permissible, but 
should be sought separately from the initial consent” 
Ireland: Irish Medicines Board (2006): IMB Guidelines 
for Pharmacogenetic Research 
Consent documents should include “the possible options for 
future use of the collected data in other research” 
United States: Consortium on Pharmacogenetics 
(2002): Pharmacogenetics: Ethical and Regulatory 
Issues in Research and Clinical Practice 
“In most cases, a reasonable policy is to obtain consent to a 
range of related studies over a defined period of time” 
 
 
(ii) Duration of consent  
The duration of consent refers to how long 
samples and/or data will be stored, as part 
of the initial study or for future research use.  
So far, only 4 documents have been 
identified that address the issue of duration 
of consent in the realm of pharmacogenomic 
research. While no consensus can be drawn 
from such a small number of policy 
statements, those that discuss the duration 
of consent were in agreement that the length 
of time for which the samples could be 
stored and studied should be included in the 
informed consent document given to 
research participants. None of the policy 
statements, however, gave an indication of 
the appropriate length of time for sample 
storage.  For example, the recommendation 
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from the Council for International 
Organizations of Medical Sciences (CIOMS) 
is very broad, suggesting that “the time 
range for storage of the samples may be for 
the duration of the study to many years 
thereafter.”17
 
 
TABLE 2: 
Document Recommendation on duration of consent  
International: Pharmacogenetics Working Group (2002): 
Elements of Informed Consent for Pharmacogenetic 
Research 
Timelines for the destruction of samples must be included 
in the consent form, however, no specified length is 
prescribed  
International: Council for International Organizations of 
Medical Sciences (2005): Pharmacogenomics: Towards 
improving treatment with medicines 
“The time range for storage of the samples may be for the 
duration of the study to many years thereafter” 
Belgium: Consultative Committee on Bioethics (2003): 
Opinion (No 26) December 15, 2003 concerning the 
introduction of pharmacogenetics in experimental protocols 
The protocol must define the period for which the sample 
is kept in an identifiable, codified or anonymous form.  
Ireland: Irish Medicines Board (2006): IMB Guidelines for 
Pharmacogenetic Research 
The consent protocol must define “[w]hat happens to the 
samples when the research is finished; whether or not 
they will be destroyed, if not, who keeps them, and for 
how long…” 
 
 
(iii) Confidentiality and coding of 
research samples 
Procedures for protecting confidentiality and 
its corollary, the protection of personal 
information and genetic samples, are 
extremely important considerations in 
pharmacogenomic research.18 A major step 
toward a more harmonized approach to 
confidentiality protection was reached in 
2002, when terminology describing the 
storage of samples was agreed upon by the 
Pharmacogenetics Working Group19 and the 
European Federation of Pharmaceutical 
Industries and Associations20 and was 
subsequently adopted by the International 
Conference on Harmonization in 2006.21  
This helped standardize the way that 
samples are coded and handled, and further 
addressed the concerns noted in several 
pharmacogenomic research guidelines. 
  
On the issue of confidentiality and coding of 
samples, many policy statements favour 
flexibility regarding the degree of protection 
that must be used with respect to biological 
samples. It is often advocated that the 
appropriate level of protection should be 
determined on a case-by-case basis.  
Decisions as to what level of coding should 
be used in a given study should be based on 
a number of factors, including: the nature of 
the research, the intended use for the 
samples, the length of sample storage, 
secondary uses, legal context, specific 
concerns raised by researchers, committees 
and sponsors, and selection of the greatest 
degree of privacy protection compatible with 
the objectives of the research. 22
 
Only the use of “identified” and “anonymous” 
samples tends to be discouraged. Identified 
samples are discouraged because they offer 
research participants insufficient privacy 
protection. The use of anonymous samples 
is discouraged for a number of reasons. It is 
ethically problematic because participants 
will not be re-contactable and therefore 
results that may be relevant to their health 
will not be returnable to them.  Anonymous 
samples also cause regulatory problems 
because a study conducted on anonymous 
samples cannot be audited or validated. 
Finally, the use of anonymous samples is 
technically problematic because of their 
limited scientific utility outside of the 
exploratory stages of research. In the 
majority of cases, samples can be coded, 
double coded or anonymized, provided that 
the chosen level of protection is justified by 
the researcher and that the participants are 
informed in the consent process. 
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TABLE 3 
Document Recommendation on coding and confidentiality 
International:  Pharmacogenetics Working Group 
(2006): Returning Genetic Research Results to 
Individuals: Points to Consider 
Anonymizing samples is not recommended for ethical (participants 
are unable to withdraw or obtain results), as well as regulatory 
(results cannot be approved with anonymous samples) reasons  
International: Pharmacogenetics Working Group 
(2002): Elements of Informed Consent for 
Pharmacogenetic Research 
The precise level of coding depends on the study and must be 
included in the consent process 
International: Council for International 
Organizations of Medical Sciences (2005): 
Pharmacogenomics: Towards improving 
treatment with medicines 
“The informed consent document should describe sample storage 
and access, along with any applicable restrictions and legal 
requirements” 
Europe: European Federation of Pharmaceutical  
Industries and Associations (2006): Key 
Messages Surrounding Pharmacogenetics 
 
The choice of how to code samples depends on five factors:  1) 
nature of the research, 2) intended use of the data, 3) legal and 
regulatory constraints, 4) position of the IRB (Institutional Review 
Board) or EC (Ethics Committee), and 5) the needs of the study 
sponsor/investigator 
Belgium: Consultative Committee on Bioethics 
(2003): Opinion (No 26) December 15, 2003 
concerning the introduction of pharmacogenetics 
in experimental protocols 
Samples should remain in a codified form until verification by a 
regulatory agency is no longer needed 
Italy: A collaboration of research groups (2002): 
Italian Proposed Guidelines for the Evaluation of 
Pharmacogenetic Research 
“The degree of anonymization of samples and data… must be 
described and justified.  Each of these levels of anonymity has 
advantages and disadvantages and the evaluation of the best 
approach must be made on a case-by-case basis” 
United Kingdom: Nuffield Council on Bioethics 
(2003): Pharmacogenetics: Ethical Issues 
“We consider that to protect the privacy of participants, the greatest 
degree of anonymity should be imposed on samples, compatible 
with fulfilling the objectives of the research” 
Ireland: Irish Medicines Board (2006): IMB 
Guidelines for Pharmacogenetic Research 
The consent form must define “the level of anonymity of the 
samples and the data” 
United States: Consortium on Pharmacogenetics 
(2002):Pharmacogenetics: Ethical and Regulatory 
Issues in Research and Clinical Practice 
Coding samples (single or double) is preferable to both identified 
and anonymous samples.  Double-coding is superior to protect 
confidentiality, but it is also costlier, thus it must be balanced 
against the risk to the subject if the information is disclosed  
 
 
(iv) Return of  research results 
Many texts recommend that “aggregate” 
results should always be made available to 
research participants, while individual results 
should only be made available when they 
contain scientifically valid and clinically 
useful information. A few texts, however, 
argue that the individual has a “right to 
know” and that patients should be given the 
choice as to whether they want to know their 
individual research results regardless of the 
utility or validity of the information.22 Despite 
these divergences, a majority of texts are in 
agreement that patients should be informed 
in the consent process as to whether results 
will or will not be made available. 
 
Many of the policy statements analyzed 
suggest that returning individual research 
results may not be relevant in 
pharmacogenomic research. This position is 
based on the view that it is highly unlikely 
that pharmacogenomic research will reveal 
clinically useful information in its current 
exploratory phase. While this may have 
been accurate in the past, many current 
pharmacogenomic studies now have the 
potential to reveal clinically useful 
information. In the future, the likelihood that 
these studies will continue to produce 
relevant information will increase.  As such, 
policy makers should move away from the 
idea that pharmacogenomics will remain 
exploratory and should begin to work on the 
premise that relevant information will arise 
out of these studies. Taking this into 
account, a more appropriate framework 
needs to be developed for determining when 
and how individually relevant results of 
pharmacogenomic studies should be 
returned to individual patients. 
(2007) vol. 5, no. 2, GenEdit, 1-9 
www.humgen.umontreal.ca/genedit 
Permission to reproduce granted if the source is correctly identified. ISSN 1718-9314 
5
TABLE 4:  
Document Recommendation on returning results 
International: Pharmacogenetics Working 
Group (2006): Returning Genetic Research 
Results to Individuals: Points to Consider 
 “If the research is exploratory a reasonable default position could be that 
no results will be proactively returned to an individual.  Specific requests 
for results could first be addressed with information about the general 
findings from the study, followed by individual results if deemed 
appropriate by law” 
International: Pharmacogenetics Working 
Group (2002): Elements of Informed 
Consent for Pharmacogenetic Research 
“It is important to describe the intended types of pharmacogenetic results 
to be derived from a study and to inform the subject about the realistic 
expectations and health implications, if any, of these results. In many 
types of pharmacogenetic studies, overall results are derived from 
analysis of aggregate genetic data (ie, population analysis); 
interpretations of data may be generally applicable to populations but are 
not specifically applicable to individual subjects” 
International: Council for International 
Organizations of Medical Sciences (2005): 
Pharmacogenomics: Towards improving 
treatment with medicines 
“Given that pharmacogenomics is in its infancy, only occasionally will 
precise, useful validated information be obtained as a result of 
pharmacogenetic research” 
 
 
Europe: European Federation of 
Pharmaceutical Industries and Associations 
(2006): Key Messages Surrounding 
Pharmacogenetics 
Although unlikely in this stage of PGx research, if individually useful 
information will be obtained in the study, participants should be given the 
option to obtain those results 
Belgium: Consultative Committee on 
Bioethics (2003): Opinion (No 26) December 
15, 2003 concerning the introduction of 
pharmacogenetics in experimental protocols 
The protocol must be clear as to if and how individual results will be 
shared, or whether only general results will be available  
Italy: A collaboration of research groups 
(2002):  Italian Proposed Guidelines for the 
Evaluation of Pharmacogenetic Research 
“After the preliminary nature of the results and their lack of clinical 
usefulness have been explained, each subject has the right to request 
and be given access to all data related to his own genetic information…  
The degree and manner by which subjects will be given access to 
genetic data about themselves… must be described” 
United Kingdom: Nuffield Council on 
Bioethics (2003): Pharmacogenetics: Ethical 
Issues 
“While we are sympathetic to the view that patients should have the 
opportunity to receive useful and validated information about their 
medical treatment, we consider that only on rare occasions will such 
information be obtained as part of research in pharmacogenetics” 
Ireland: Irish Medicines Board (2006):  
IMB Guidelines for Pharmacogenetic 
Research 
The patient should be given the opportunity “to be informed of any future 
results using his/her samples” 
United States: Consortium on 
Pharmacogenetics (2002): 
Pharmacogenetics: Ethical and Regulatory 
Issues in Research and Clinical Practice 
“The obligation of the researcher to disclose potentially beneficial 
information to subjects who opt for disclosure extends only to reliable 
information” 
 
 
(v) Consent to pharmacogenomic 
‘add-on’ studies in clinical trials 
Pharmacogenomic “add-on” studies refers to 
studies conducted alongside clinical trials, 
but that are not usually essential to 
participation in the main clinical study. The 
“add-on” can be distinguished on two fronts: 
the first type of “add-on” study asks 
permission to carry out genetic research on 
specific genetic variants that are expected to 
influence the drug(s) being investigated in 
the clinical trial. This genetic information is 
linked to personal and medical history and 
the sample is “identifiable”. The second type 
of “add-on” study asks to store the samples 
after completion of the clinical trial for a long 
or unlimited period in order to carry out 
future, yet unspecified research. The 
question thus arises as to how one handles 
the consent form in the context of these 
research scenarios. Can a single consent 
form address both the clinical trial and 
pharmacogenomic sub-studies?  
 
As shown in Table 5, the majority of policy 
statements recommend the use of a 
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separate consent form for the 
pharmacogenomic portion of studies.  The 
purpose of a separate consent is to highlight 
the fact that participants are free to 
participate in additional studies, and that 
declining to do so will not impact their 
involvement in the main study.  However, 
CIOMS noted, interestingly, that while this 
has been the standard for 
pharmacogenomics research due to its 
novelty, this standard will most likely change 
as pharmacogenomics becomes more 
integral to the drug development and 
approval process.23  For example, while 
Health Canada advocates that a separate 
consent form be used when add-on studies 
are initiated separately from the main clinical 
study, they specifically make an exception 
for situations where participation in the 
pharmacogenomic portion of the study is “a 
condition for participation”.24 This will likely 
be the case when prior genotyping is used 
as part of inclusion criteria to address safety 
considerations for participation in a trial. It 
will be interesting to see how policies evolve 
as pharmacogenomics becomes more 
mainstream and whether the request to 
store samples for unlimited periods and for 
unspecified research will continue to require 
additional consent. 
 
TABLE 5:  
Document Recommendation on Separate Consent 
International: Pharmacogenetics 
Working Group (2002): Elements of 
Informed Consent for Pharmacogenetic 
Research 
A separate consent form explaining the PGx component of the study should be 
provided unless participation in the clinical and PGx studies are both required 
aspects of participation.  
International: Council for International 
Organizations of Medical Sciences 
(2005): Pharmacogenomics: Towards 
improving treatment with medicines 
“A separate informed consent has become quasi-standard… However, as the 
field develops more studies are likely to include genotype as an integral part of 
determining a drug’s profile and/or as an inclusion criterion, shifting the quasi-
standard towards a single consent form” 
Italy: A collaboration of research groups 
(2002): Italian Proposed Guidelines for 
the Evaluation of Pharmacogenetic 
Research 
“It would be preferable that the subject submits one consent for the clinical study 
and the other consent for the genetic study.  This permits the subject to 
participate in the clinical study without necessarily also participating in the PGx 
study” 
United Kingdom: Nuffield Council on 
Bioethics (2003): Pharmacogenetics: 
Ethical Issues 
Broad consent “should be sought separately from consent to the initial study.  
This separate consent may be obtained when the samples are initially taken, or 
at a later date” 
Ireland Irish Medicines Board (2006):  
IMB Guidelines for Pharmacogenetic 
Research 
“It is preferable that the subject submits one consent for the clinical study, and 
another consent for the genetic study. This allows the subject to focus on each 
aspect of the study, and also permits the subject to participate in the clinical 
study without necessarily also participating in the pharmacogenetic part” 
Canada: Health Canada (2007): 
Guidance Document: Submission of 
Pharmacogenomic Information 
“When clinical trial sponsors intend to collect samples for exploratory 
pharmacogenomic testing outside the scope of the main clinical trial, informed 
consent should be obtained separately from that of the main trial.” However, a 
new consent is not needed where the pharmacogenetic test is “a condition of 
participation” 
Belgium: Consultative Committee on 
Bioethics (2003): Opinion (No 26) 
December 15, 2003 concerning the 
introduction of pharmacogenetics in 
experimental protocols 
“We recommend that data for the pharmacogenomic add-on study be given on a 
separate consent form to ensure that the patient is perfectly informed of the 
particularities of the pharmacogenomic study (translation)” 
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Conclusion 
This comparative review of the informed 
consent process in pharmacogenomic 
research addresses several key issues 
associated with pharmacogenomic research 
including: scope of consent, duration of 
consent, confidentiality and coding of 
research samples, return of research 
results, and consent to ‘add-on’ studies 
during clinical trials.  
 
While this informed consent analysis is 
framed in the context of pharmacogenomic 
research, it is underpinned by the informed 
consent process in genomic research in 
general. This analysis demonstrates that 
very few recommendations or guidelines 
specifically explicitly address the 
requirements for the informed consent 
process in relation to pharmacogenomic 
research.  Moreover, the guidelines that do 
exist do not always adequately address the 
technological advances in genotyping that 
now allow for samples to be genotyped for 
millions of single nucleotide polymorphisms 
(SNPs) cheaply and simultaneously.25 Given 
adequate facilities and expertise, and with 
little effort, this information will become 
unique and theoretically could always be 
identified.27
 
As this analysis has demonstrated, there is 
little consensus concerning the requirements 
of informed consent for pharmacogenomic 
research. In relation to the scope of consent, 
guiding documents propose a diverse range 
of solutions to balance the rights of research 
participants with the importance of allowing 
the progress of research. Duration of 
consent is rarely discussed in the majority of 
guidance documents.26 The need to 
describe the timeline for the use and storage 
of the samples, and to include and explain 
this timeline in the consent process are the 
only recommendations made in the few 
documents that mention this issue.27 In 
terms of confidentiality, there is tension 
between the desire to protect participants’ 
personal information and the importance of 
maintaining a link with the participant identity 
to be able to access the phenotypic 
information necessary to conduct 
translational pharmacogenomic research. 
Little guidance exists primarily because this 
type of determination must be made on a 
case-by-case basis.28  In terms of returning 
individual research results, it is recognized 
that there is a right to know (or not to know) 
results, particularly when such results 
become clinically relevant. There seems to 
be a consensus that returning 
pharmacogenomic research results to 
participants is premature at this exploratory 
stage because current results do not meet 
the standards of scientific validity and 
clinical usefulness. However, this will soon 
cease to be the case as studies become 
more advanced; and therefore the issue of 
returning individual results needs to be re-
evaluated in the near future. Finally, 
concerning how consent should be handled 
for pharmacogenomic add-on studies, there 
is recognition that investigators need to 
obtain separate informed consent for 
pharmacogenomic studies that are added on 
to a main clinical study. This requirement 
could be abandoned as pharmacogenomics 
becomes more integrated and routine within 
the drug approval process.29  
 
In summary, pharmacogenomic research 
presents a number of important ethical 
challenges for the informed consent 
process.  This analysis indicates that further 
guidance is needed to address the ethical 
considerations if pharmacogenomics is to be 
well-received by policy makers and the 
general public. It has become increasingly 
difficult for pharmacogenomic researchers to 
navigate their way across generic 
recommendations for genetic research that 
may not be relevant in the context of 
pharmacogenomics and across an 
insufficient number of specific guidelines 
that would often need to be reviewed to 
reflect the new reality of a science in 
constant evolution. Many more studies and 
much more discussion, recommendations 
and guidance are needed to enable 
pharmacogenomic research to move 
forward ethically and efficiently.  
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